Anisodamine hydrobromide in the treatment of critically ill patients with septic shock: a multicenter randomized controlled trial

References

• Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1–9. doi: 10.1007/s00134-021-06506-y.
   PubMed Web of Science ®Google Scholar
• Martín S, Pérez A, Aldecoa C. Sepsis and immunosenescence in the elderly patient: a review. Front Med (Lausanne). 2017;4:20. doi: 10.3389/fmed.2017.00020.
   PubMed Web of Science ®Google Scholar
• Oh SY, Cho S, Kim GH, et al. Incidence and outcomes of sepsis in korea: a nationwide cohort study from 2007 to 2016. Crit Care Med. 2019;47(12):e993–e998. doi: 10.1097/CCM.0000000000004041.
   PubMed Web of Science ®Google Scholar
• Petros S, John S. The guideline of surviving sepsis campaign sepsis 2016. Med Klin Intensivmed Notfmed. 2017;112(5):454–458. doi: 10.1007/s00063-017-0298-5.
   PubMed Web of Science ®Google Scholar
• Bauer M, Gerlach H, Vogelmann T, et al. Mortality in sepsis and septic shock in Europe, North america and Australia between 2009 and 2019- results from a systematic review and meta-analysis. Crit Care. 2020;24(1):239. doi: 10.1186/s13054-020-02950-2.
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). J Am Med Assoc. 2016;315(8):801–810. doi: 10.1001/jama.2016.0287.
   PubMed Web of Science ®Google Scholar
• Coopersmith CM, De Backer D, Deutschman CS, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Med. 2018;44(9):1400–1426. doi: 10.1007/s00134-018-5175-z.
   PubMed Web of Science ®Google Scholar
• Tarbell JM, Cancel LM. The glycocalyx and its significance in human medicine. J Intern Med. 2016;280(1):97–113. doi: 10.1111/joim.12465.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med. 1995;333(16):1025–1032. doi: 10.1056/NEJM199510193331601.
   PubMed Web of Science ®Google Scholar
• Sakr Y, Dubois MJ, De Backer D, et al. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004;32(9):1825–1831. doi: 10.1097/01.ccm.0000138558.16257.3f.
   PubMed Web of Science ®Google Scholar
• Charlton M, Sims M, Coats T, et al. The microcirculation and its measurement in sepsis. J Intensive Care Soc. 2017;18(3):221–227. doi: 10.1177/1751143716678638.
   PubMedGoogle Scholar
• Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine. J Appl Toxicol. 2007;27(2):116–121. doi: 10.1002/jat.1154.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18. (doi: 10.1186/1741-7015-8-18.
   PubMed Web of Science ®Google Scholar
• Das S, Mitra K, Mandal M. Sample size calculation: basic principles. Indian J Anaesth. 2016;60(9):652–656. doi: 10.4103/0019-5049.190621.
   PubMed Web of Science ®Google Scholar
• Poston JT, Koyner JL. Sepsis associated acute kidney injury. BMJ. 2019;364:k4891. doi: 10.1136/bmj.k4891.
   PubMed Web of Science ®Google Scholar
• Ruan QR, Zhang WJ, Hufnagl P, et al. Anisodamine counteracts lipopolysaccharide-induced tissue factor and plasminogen activator inhibitor-1 expression in human endothelial cells: contribution of the NF-kappa b pathway. J Vasc Res. 2001;38(1):13–19. doi: 10.1159/000051025.
   PubMed Web of Science ®Google Scholar
• Sheng CY, Gao WY, Guo ZR, et al. Anisodamine restores bowel circulation in burn shock. Burns. 1997;23(2):142–146. doi: 10.1016/s0305-4179(96)00086-1.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zou J, Wan F, et al. Update on the sources, pharmacokinetics, pharmacological action, and clinical application of anisodamine. Biomed Pharmacother. 2023;161:114522. doi: 10.1016/j.biopha.2023.114522.
   PubMed Web of Science ®Google Scholar
• Su JY. Cell protection mechanism of antishock action of anisodamine. Chin Med J (Engl). 1992;105(12):976–979.
   PubMed Web of Science ®Google Scholar
• Su JY, Wu L, Tang C. Experimental study in rabbits of the antishock effect of anisodamine (654-2), and its mechanism of action. Resuscitation. 1983;10(3):173–184. doi: 10.1016/0300-9572(83)90005-9.
   PubMed Web of Science ®Google Scholar
• Xiu RJ, Hammerschmidt DE, Coppo PA. Anisodamine inhibits thromboxane synthesis, granulocyte aggregation and platelet aggregation. J Am Med Assoc. 1982;247(10):1458–1460.
   Web of Science ®Google Scholar
• Wan F, Du X, Liu H, et al. Protective effect of anisodamine hydrobromide on lipopolysaccharide-induced acute kidney injury. Biosci Rep. 2020;40(7):BSR20201812. doi: 10.1042/BSR20201812.
   Google Scholar
• Du X, Liu H, Yue Y, et al. Anisodamine hydrobromide protects glycocalyx and against the lipopolysaccharide-induced increases in microvascular endothelial layer permeability and nitric oxide production. Cardiovasc Eng Technol. 2021;12(1):91–100. doi: 10.1007/s13239-020-00486-8.
   PubMed Web of Science ®Google Scholar
• Yang J, Dong GJ, Wang HW, et al. Influence of microcirculatory dysfunction on myocardial injury after cardiopulmonary resuscitation. Biomed Environ Sci. 2022;35(4):334–344.
   PubMed Web of Science ®Google Scholar
• Chai J, Yang H, Sheng Z, et al. Anisodamine in prevention and treatment of sepsis of severely burned patients. Zhonghua Wai Ke Za Zhi. 2000;38(9):686–689.
   PubMedGoogle Scholar
• Yu Y, Zhu C, Hong Y, et al. Effectiveness of anisodamine for the treatment of critically ill patients with septic shock: a multicentre randomized controlled trial. Crit Care. 2021;25(1):349. doi: 10.1186/s13054-021-03774-4.
   PubMed Web of Science ®Google Scholar
• Zhu CP, Jiang F, Wang RQ, et al. Comparison of efficacy and safety of hyoscine butylbromide versus anisodamine for acute gastric or intestinal spasm-like pain: a randomized, double-blinded, multicenter phase III trial. J Dig Dis. 2017;18(8):453–460. doi: 10.1111/1751-2980.12504.
   PubMed Web of Science ®Google Scholar
• Backer DD, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789. doi: 10.1056/NEJMoa0907118.
   PubMed Web of Science ®Google Scholar